High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
暂无分享,去创建一个
A. Mes-Masson | D. Provencher | L. Buisseret | D. Allard | S. Robson | P. Chrobak | R. Lapointe | I. Cousineau | J. Stagg | L. Communal | S. Pommey | M. Carneiro | Y. Bareche | P. Thébault
[1] S. Robson,et al. Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis. , 2020, Journal of hepatology.
[2] A. Khoruts,et al. Sensing of ATP via the Purinergic Receptor P2RX7 Promotes CD8+ Trm Cell Generation by Enhancing Their Sensitivity to the Cytokine TGF-β. , 2020, Immunity.
[3] L. Buisseret,et al. The adenosine pathway in immuno-oncology , 2020, Nature Reviews Clinical Oncology.
[4] R. Knobler,et al. Recent advances in understanding and managing cutaneous T-cell lymphomas , 2020, F1000Research.
[5] P. Park,et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer , 2020, Nature Communications.
[6] E. Vadillo,et al. Myo1e modulates the recruitment of activated B cells to inguinal lymph nodes , 2020, Journal of Cell Science.
[7] Manish R. Patel,et al. Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response , 2020, Clinical Cancer Research.
[8] R. Drapkin,et al. Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment , 2020, Cell reports.
[9] J. Madore,et al. Targeting CD39 in cancer reveals an extracellular ATP and inflammasome driven tumor immunity. , 2019, Cancer discovery.
[10] P. LoRusso,et al. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies , 2019, Journal of Immunotherapy for Cancer.
[11] G. Coukos,et al. Immunotherapy in Ovarian Cancer: Are We There Yet? , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Swisher,et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. , 2019, JAMA oncology.
[13] D. Provencher,et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] P. Bose,et al. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure , 2018, Nature Communications.
[15] Christoph Hafemeister,et al. Comprehensive integration of single cell data , 2018, bioRxiv.
[16] Gregory M. Chen,et al. Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma , 2018, Clinical Cancer Research.
[17] D. Gerhard,et al. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma , 2018, Clinical Cancer Research.
[18] M. Fehlings,et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.
[19] C. Le Page,et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers , 2018, BMC Cancer.
[20] U. Cavallaro,et al. CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells , 2018, Stem cell reports.
[21] A. Whittemore,et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer , 2017, JAMA oncology.
[22] Boxi Kang,et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing , 2017, Cell.
[23] Deborah S. Barkauskas,et al. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. , 2016, Cancer cell.
[24] J. Wischhusen,et al. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape , 2016, Journal of Immunotherapy for Cancer.
[25] Benjamin Haibe-Kains,et al. MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature , 2016, Scientific Reports.
[26] Joel S. Parker,et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..
[27] E. Nevedomskaya,et al. A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity. , 2016, Journal of proteome research.
[28] R. Broaddus,et al. Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. , 2015, The Journal of clinical investigation.
[29] P. Linsley,et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data , 2015, Genome Biology.
[30] Deena M. A. Gendoo,et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. , 2015, Cancer research.
[31] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[32] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[33] Todd H. Stokes,et al. Removing Batch Effects From Histopathological Images for Enhanced Cancer Diagnosis , 2014, IEEE Journal of Biomedical and Health Informatics.
[34] M. Smyth,et al. Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs , 2013, Clinical Cancer Research.
[35] S. Loi,et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer , 2013, Proceedings of the National Academy of Sciences.
[36] Jung-Hye Choi,et al. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration , 2012, Journal of gynecologic oncology.
[37] G. Coukos,et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.
[38] T. Curiel,et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. , 2011, The Journal of clinical investigation.
[39] Bin Zhang. CD73: a novel target for cancer immunotherapy. , 2010, Cancer research.
[40] for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.
[41] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[42] Editeur,et al. The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27 , 2017 .
[43] Deena M. A. Gendoo,et al. CD 73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer , 2015 .